Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Completed · Phase 2

Conditions studied: Myelodysplastic Syndrome, MDS, Trisomy 8

In brief

The primary objectives of this study are to determine if rigosertib sodium, given orally in the form of soft gel capsules, is safe and is associated with a reduction in the number of blood transfusion units that are needed in patients with myelodysplastic syndrome (MDS) classified as Low or Intermediate-1 (Int-1) (any cytogenetics) or trisomy 8 Intermediate 2 (Int-2) in the International Prognostic Scoring System (IPSS) who are transfusion-dependent. Rigosertib will be taken on days 1 to 21 of a 21-day cycle.

Key facts

Study ID: NCT01584531
Run by: Traws Pharma, Inc.
People needed: 82
Starts: 2012-05-01
Expected to finish: 2015-11-01
Last updated by the study team: 2017-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosis of MDS confirmed by bone marrow aspirate and/or biopsy within 6 weeks prior to first dose of study drug according to World Health Organization (WHO) or French-American-British (FAB) classification
MDS classified as Low risk or Int-1 risk (any cytogenetics) or Trisomy 8 Int-2 risk, according to IPSS classification
Transfusion dependency defined by at least 4 units of RBC administered within 8 weeks before baseline
Off all other treatments for MDS (azacitidine, decitabine, lenalidomide, chemotherapy, immunosuppressive agents) for at least 4 weeks
ECOG performance status of 0, 1 or 2

You may not qualify if…

Ongoing clinically significant anemia due to factors such as iron, B12, or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI) bleeding, unless stabilized for 1 week after RBC transfusion
Serum ferritin <50 ng/mL
Hypoplastic MDS (cellularity <10%)
Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast
Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
Active infection not adequately responding to appropriate therapy
Total bilirubin ≥1.5 mg/dL not related to hemolysis or Gilbert's disease
ALT/AST ≥2.5 x upper limit of normal (ULN)
Serum creatinine ≥2.0 mg/dL
Ascites requiring active medical management including paracentesis
Hyponatremia (defined as serum sodium value of <130 mEq/L)
Female patients who are pregnant or lactating
Patients who are unwilling to follow strict contraception requirements
Female patients with reproductive potential who do not have a negative urine beta-human chorionic gonadotropin (bHCG) pregnancy test at Screening
Major surgery without full recovery or major surgery within 3 weeks of rigosertib treatment start
Uncontrolled hypertension (defined as a systolic pressure ≥160 mmHg and/or a diastolic pressure ≥110 mmHg)
New onset seizures (within 3 months prior to the first dose of rigosertib) or poorly controlled seizures
Any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy
Chronic use (>2 weeks) of corticosteroids (>10 mg/24 hr equivalent prednisone) within 4 weeks of starting rigosertib
Investigational therapy within 4 weeks of starting rigosertib
Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements

Where it is running

Mayo Clinic — Scottsdale, Arizona, United States
Winship Cancer Institute, Emory University — Atlanta, Georgia, United States
Mayo Clinic — Rochester, Minnesota, United States
Columbia University Medical Center — New York, New York, United States
Bon Secours St. Francis Hospital — Greenville, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.